Back ريفاروكسابان Arabic ریواروکسابان AZB Rivaroxaban German Ριβαροξαμπάνη Greek Rivaroxabán Spanish ریواروکسابان Persian Rivaroksabaani Finnish Rivaroxaban French ריברוקסבאן HE Ռիվարոքսաբան Armenian
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Xarelto, others |
| Other names | BAY 59-7939 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a611049 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 80–100%; Cmax = 2–4 hours (10 mg oral)[4] |
| Metabolism | CYP3A4, CYP2J2 and CYP-independent mechanisms[4] |
| Elimination half-life | 5–9 hours in healthy subjects aged 20 to 45[4][7] |
| Excretion | 2/3 metabolized in liver and 1/3 eliminated unchanged[4] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.210.589 |
| Chemical and physical data | |
| Formula | C19H18ClN3O5S |
| Molar mass | 435.88 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots.[8] Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery.[8] It is taken by mouth.[8]
Common side effects include bleeding.[8] Other serious side effects may include spinal hematoma and anaphylaxis.[8] It is unclear if use in pregnancy and breastfeeding is safe.[1] Compared to warfarin it has fewer interactions with other medications.[9] It works by blocking the activity of the clotting protein factor Xa.[8]
Rivaroxaban was patented in 2007 and approved for medical use in the United States in 2011.[10] In the United States, it will not be available as a generic medication until 2024.[11][12] It is on the World Health Organization's List of Essential Medicines.[13] In 2021, it was the 86th most commonly prescribed medication in the United States, with more than 8 million prescriptions.[14][15]
- ^ a b "Rivaroxaban Use During Pregnancy". Drugs.com. Retrieved March 3, 2019.
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved October 22, 2023.
- ^ Xarelto (Bayer Australia Ltd)
- ^ a b c d e "Xarelto 2.5 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). August 9, 2022. Retrieved November 9, 2022.
- ^ Cite error: The named reference
Xarelto FDA labelwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Xarelto EPARwas invoked but never defined (see the help page). - ^ Abdulsattar Y, Bhambri R, Nogid A (May 2009). "Rivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor xa inhibitor". P & T. 34 (5): 238–44. PMC 2697099. PMID 19561868.
- ^ a b c d e f "Rivaroxaban Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved March 3, 2019.
- ^ Kiser K (2017). Oral Anticoagulation Therapy: Cases and Clinical Correlation. Springer. p. 11. ISBN 9783319546438.
- ^ "Generic Xarelto Availability". Drugs.com. Retrieved May 9, 2017.
- ^ "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations". www.accessdata.fda.gov. Retrieved April 24, 2019.
- ^ "Bayer, J&J Win Ruling That Upholds Patent for Xarelto Drug". April 22, 2019. Retrieved April 24, 2019.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- ^ "The Top 300 of 2021". ClinCalc. Archived from the original on January 15, 2024. Retrieved January 14, 2024.
- ^ "Rivaroxaban - Drug Usage Statistics". ClinCalc. Retrieved January 14, 2024.